Frequent epigenetic inactivation of KIBRA, an upstream member of the salvador/warts/ hippo (SWH) tumor suppressor network, is associated with specific genetic event in B-cell acute lymphocytic leukemia

Epigenetics

Volumn 6, Issue 3, 2011, Pages 326-332

  Hill, Victoria K ^a   Dunwell, Thomas ^a   Catchpoole, Daniel ^b   Krex, Dietmar ^c   Brini, Anna T ^d   Griffiths, Mike ^e   Craddock, Charles ^f   Maher, Eamonn R ^a   Latif, Farida ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d UNIVERSITY OF MILAN   (Italy)

^e BIRMINGHAM WOMEN S HOSPITAL   (United Kingdom)

^f QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

ALL; ETV6 RUNX1 translocation; KIBRA; Methylation; SWH pathway

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; PROTEIN KIBRA; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR RUNX1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; B CELL LEUKEMIA; CANCER DIAGNOSIS; CHROMOSOME 12; CHROMOSOME 21; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; GENE INACTIVATION; GENE SILENCING; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMIA REMISSION; LEUKEMOGENESIS; RECIPROCAL CHROMOSOME TRANSLOCATION; T CELL LEUKEMIA; TUMOR SUPPRESSOR GENE;

MAMMALIA;

EID: 79952397324     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.6.3.14404     Document Type: Article

References (38)

1. Harvey K, Tapon N. The Salvador-Warts-Hippo pathway- an emerging tumour-suppressor network. Nat Rev Cancer 2007; 7:182-91.
2. Zeng Q, Hong W. The emerging role of the hippo pathway in cell contact inhibition, organ size control and cancer development in mammals. Cancer Cell 2008; 13:188-92.
3. Yu J, Zheng Y, Dong J, Klusza S, Deng WM, Pan D. Kibra functions as a tumor suppressor protein that regulates Hippo signaling in conjunction with Merlin and Expanded. Dev Cell 2010; 18:288-99.
4. Genevet A, Wehr MC, Brain R, Thompson BJ, Tapon N. Kibra is a regulator of the Salvador/Warts/Hippo signaling network. Dev Cell 2010; 18:300-8.
5. Baumgartner R, Poernbacher I, Buser N, Hafen E, Stocker H. The WW domain protein Kibra acts upstream of Hippo in Drosophila. Dev Cell 2010; 18:309-16.
6. Richter AM, Pfeifer GP, Dammann RH. The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim Biophys Acta 2009; 1796:114-28.
7. Sherwood V, Manbodh R, Sheppard C, Chalmers AD. RASSF7 is a member of a new family of RAS association domain-containing proteins and is required for completing mitosis. Mol Biol Cell 2008; 19:1772-82.
8. Underhill-Day N, Hill V, Latif F. N-terminal RASSF family (RASSF7-RASSF10). Epigenetics 2011; 6: 284-92.
9. Guo C, Tommasi S, Liu L, Yee JK, Dammann R, Pfeifer GP. RASSF1A is part of a complex similar to the Drosophila Hippo/Salvador/Lats tumor-suppressor network. Curr Biol 2007; 17:700-5.
10. Matallanas D, Romano D, Yee K, Meissl K, Kucerova L, Piazzolla D, et al. RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein. Mol Cell 2007; 27:962-75.
11. Dallol A, Hesson LB, Matallanas D, Cooper WN, O'Neill E, Maher ER, et al. RAN GTPase is a RASSF1A effector involved in controlling microtubule organization. Curr Biol 2009; 19:1227-32.
12. Dallol A, Kolch W, Latif F. When RASSF1A RAN into tumor suppression: Ran GTPase is a RASSF1A effector involved in controlling microtubule organization. Cell Cycle 2009; 8:3796-7.
13. Hesson LB, Dunwell TL, Cooper WN, Catchpoole D, Brini AT, Chiaramonte R, et al. The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias. Mol Cancer 2009; 8:42.
14. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006; 354:166-78.
15. Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358:1148-59.
16. Galm O, Herman JG, Baylin SB. The fundamental role of epigenetics in hematopoietic malignancies. Blood Rev 2006; 20:1-13.
17. Dunwell T, Hesson L, Rauch TA, Wang L, Clark RE, Dallol A, et al. A genome-wide screen identifies frequently methylated genes in haematological and epithelial cancers. Mol Cancer 2010; 9:44.
18. Martin-Subero JI, Ammerpohl O, Bibikova M, Wickham-Garcia E, Agirre X, Alvarez S, et al. A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms. PLoS One 2009; 4:6986.
19. Kuang SQ, Tong WG, Yang H, Lin W, Lee MK, Fang ZH, et al. Genome-wide identification of aberrantly methylated promoter associated CpG islands in acute lymphocytic leukemia. Leukemia 2008; 22:1529-38.
20. Avruch J, Xavier R, Bardeesy N, Zhang XF, Praskova M, Zhou D, et al. Rassf family of tumor suppressor polypeptides. J Biol Chem 2009; 284:11001-5.
21. Vichalkovski A, Gresko E, Cornils H, Hergovich A, Schmitz D, Hemmings BA. NDR kinase is activated by RASSF1A/MST1 in response to Fas receptor stimulation and promotes apoptosis. Curr Biol 2008; 18:1889-95.
22. Zender L, Spector MS, Xue W, Flemming P, Cordon- Cardo C, Silke J, et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 2006; 125:1253-67.
23. Zhou D, Conrad C, Xia F, Park JS, Payer B, Yin Y, et al. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell 2009; 16:425-38.
24. Lu L, Li Y, Kim SM, Bossuyt W, Liu P, Qiu Q, et al. Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci USA 2010; 107:1437-42.
25. Song H, Mak KK, Topol L, Yun K, Hu J, Garrett L, et al. Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression. Proc Natl Acad Sci USA 2010; 107:1431-6.
26. Lee KP, Lee JH, Kim TS, Kim TH, Park HD, Byun JS, et al. The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size and liver tumorigenesis. Proc Natl Acad Sci USA 2010; 107:8248-53.
27. Kremerskothen J, Plaas C, Büther K, Finger I, Veltel S, Matanis T, et al. Characterization of KIBRA, a novel WW domain-containing protein. Biochem Biophys Res Commun 2003; 300:862-7.
28. Rosse C, Formstecher E, Boeckeler K, Zhao Y, Kremerskothen J, White MD, et al. An aPKC-exocyst complex controls paxillin phosphorylation and migration through localised JNK1 activation. PLoS Biol 2009; 7:1000235.
29. Büther K, Plaas C, Barnekow A, Kremerskothen J. KIBRA is a novel substrate for protein kinase Czeta. Biochem Biophys Res Commun 2004; 317:703-7.
30. Steinmann K, Sandner A, Schagdarsurengin U, Dammann RH. Frequent promoter hypermethylation of tumor-related genes in head and neck squamous cell carcinoma. Oncol Rep 2009; 22:1519-26.
31. Seidel C, Schagdarsurengin U, Blümke K, Würl P, Pfeifer GP, Hauptmann S, et al. Frequent hypermethylation of MST1 and MST2 in soft tissue sarcoma. Mol Carcinog 2007; 46:865-71.
32. Jiang Z, Li X, Hu J, Zhou W, Jiang Y, Li G, et al. Promoter hypermethylation-mediated downregulation of LATS1 and LATS2 in human astrocytoma. Neurosci Res 2006; 56:450-8.
33. Takahashi Y, Miyoshi Y, Takahata C, Irahara N, Taguchi T, Tamaki Y, et al. Downregulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin Cancer Res 2005; 11:1380-5.
34. Jiménez-Velasco A, Román-Gómez J, Agirre X, Barrios M, Navarro G, Vázquez I, et al. Downregulation of the large tumor suppressor 2 (LATS2/KPM) gene is associated with poor prognosis in acute lymphoblastic leukemia. Leukemia 2005; 19:2347-50.
35. Hartmann EM, Campo E, Wright G, Lenz G, Salaverria I, Jares P, et al. Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. Blood 2010; 116:953-61.
36. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Castillejo JA, Navarro G, Calasanz MJ, et al. CpG island methylator phenotype redefines the prognostic effect of t(12;21) in childhood acute lymphoblastic leukemia. Clin Cancer Res 2006; 12:4845-50.
37. Morrow M, Horton S, Kioussis D, Brady HJ, Williams O. TEL-AML1 promotes development of specific hematopoietic lineages consistent with preleukemic activity. Blood 2004; 103:3890-6.
38. Hesson L, Bièche I, Krex D, Criniere E, Hoang-Xuan K, Maher ER, et al. Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomas. Oncogene 2004; 23:2408-19.